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Background: Long interspersed nucleotide element 1 (LINE-1) hypomethylation is suggested to play a role in the
progression of colorectal cancer (CRC). To assess intra-patient heterogeneity of LINE-1 methylation in CRC and to
understand its biological relevance in invasion and metastasis, we evaluated the LINE-1 methylation at multiple
tumor sites. In addition, the influence of stromal cell content on the measurement of LINE-1 methylation in tumor
tissue was analyzed.
Methods: Formalin-fixed paraffin-embedded primary tumor tissue was obtained from 48 CRC patients. Matched
adjacent normal colon tissue, lymph node metastases and distant metastases were obtained from 12, 18 and 7 of
these patients, respectively. Three different areas were microdissected from each primary tumor and included the
tumor center and invasive front. Normal mucosal and stromal cells were also microdissected for comparison with
the tumor cells. The microdissected samples were compared in LINE-1 methylation level measured by multicolor
MethyLight assay. The assay results were also compared between microdissected and macrodissected tissue
samples.
Results: LINE-1 methylation within primary tumors showed no significant intra-tumoral heterogeneity, with the
tumor center and invasive front showing identical methylation levels. Moreover, no difference in LINE-1 methylation
was observed between the primary tumor and lymph node and distant metastases from the same patient. Tumor
cells showed significantly less LINE-1 methylation compared to adjacent stromal and normal mucosal epithelial
cells. Consequently, LINE-1 methylation was significantly lower in microdissected samples compared to
macrodissected samples. A trend for less LINE-1 methylation was also observed in more advanced stages of CRC.
Conclusions: LINE-1 methylation shows little intra-patient tumor heterogeneity, indicating the suitability of its use
for molecular diagnosis in CRC. The methylation is relatively stable during CRC progression, leading us to propose a
new concept for the association between LINE-1 methylation and disease stage.
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Global DNA hypomethylation is frequently observed in
various malignancies including colorectal cancer (CRC)
[1,2], where it is thought to play a pivotal role in car-
cinogenesis [3]. One of the possible mechanisms for the
involvement of DNA hypomethylation in cancer devel-
opment is through the activation of long interspersed
nucleotide element-1 (LINE-1) and genomic instability
[4,5]. LINE-1 is a non-long-terminal-repeat class of ret-
roposon. It is the most successfully integrated mobile
element and accounts for about 18% of the human gen-
ome [6]. LINE-1 has the potential to transpose in the
human genome, thus creating new genetic sequences
that are one of the driving forces of human evolution
[7,8]. Although the majority of LINE-1-derived elements
in the human genome no longer have the ability to
transpose due to mutations and deletions in their se-
quence, approximately 100 full-length copies of LINE-1
retain this ability [9,10]. Global DNA hypomethylation
is also accompanied by hypomethylation of LINE-1
promoter [11], suggested to result in aberrant expres-
sion and active transposition of this sequence. The
hypomethylation and/or transposition of LINE-1 ele-
ments during carcinogenesis have been suggested to
alter the transcriptome [12] and to play a role in the
acquisition of multiple cancer phenotypes including
invasion and metastasis.
Consistent with the suggested link between LINE-1
hypomethylation and carcinogenesis, previous studies
reported that LINE-1 methylation levels are lower in
more advanced stages of CRC, leading to the concept of
a progressive loss of genomic methylation during CRC
development [13]. The inverse association between
LINE-1 methylation and CRC stage suggested that
LINE-1 hypomethylation was causally involved in the ac-
quisition of invasive and metastatic phenotypes since
these are critical factors in TNM staging. If this was
true, the LINE-1 methylation level could be expected to
differ between the tumor center and invasive front, and
between primary and metastatic tumor tissue from the
same patient. However, previous studies have only
measured LINE-1 methylation in the primary tumor
and it is still unknown whether this differs from meta-
static lesions.
Aside from its biological relevance, the possible het-
erogeneity of LINE-1 methylation is a potential problem
for any clinical application using the methylation status.
Molecular analyses of tumor samples are generally per-
formed using biopsy specimens obtained prior to surgery,
or using the surgically resected tissue. Because tissue
from metastatic deposits is not easily accessible, results
obtained from analysis of the primary tumor are used in
clinical decision making. The strategies based on molecu-
lar analysis assume the marker shows no significant intra-patient heterogeneity. However, this issue is rarely investi-
gated for candidate prognostic and predictive markers.
LINE-1 methylation is a promising prognostic factor
in CRC [14] and may also be a predictive marker for the
response to fluoropyrimidines in microsatellite stable
and CpG island methylator phenotype-negative CRC
[15]. For LINE-1 methylation to be used in personalized
medicine, the intra-patient heterogeneity of this molecu-
lar marker first needs to be established. Furthermore,
the impact of contamination of tumor tissue with stro-
mal cells on the analysis of LINE-1 methylation also
needs to be investigated. A previous study showed that
stromal cells such as fibroblasts and infiltrating lympho-
cytes have significantly higher LINE-1 methylation levels
compared to the adjacent tumor cells [13]. The degree
of contamination of tumor specimens with stromal cells
could therefore compromise the accuracy of LINE-1
methylation assays. Laser-capture microdissection (LCM)
can reduce this interference by allowing the exclusive col-
lection of tumor cells. However, LCM is labor intensive
and time consuming compared to the use of whole tumor
tissue for molecular diagnosis. Comparison of the results
for LINE-1 methylation levels in microdissected tumors
compared to whole tumors should resolve whether con-
tamination with stromal cells has a significant influence
on the measurement of this marker.
The issues of intra-patient heterogeneity and contam-
ination with stromal cells were addressed in this study
to increase our understanding of LINE-1 methylation in
cancer biology, as well as for possible future clinical
applications of this marker in CRC. Using LCM, CRC
samples were collected from multiple sites including the
center and invasive front of primary tumors, as well as
from lymph node and distant metastases. LINE-1 methy-
lation levels were found to show little intra-patient het-
erogeneity, indicating this marker is suitable for clinical
applications. Stromal cells significantly influenced the
measurement of LINE-1 methylation in tumors, demon-
strating the need for LCM. Finally, from a biological per-
spective the prevailing view of a progressive loss of
genomic methylation during CRC development was not
supported in this study. Instead, we propose another
mechanism to explain the link between LINE-1 methyla-
tion and disease stage in CRC.
Materials and methods
Patients and tissue samples
Formalin-fixed paraffin-embedded (FFPE) CRC tissue
specimens were obtained from 48 patients who under-
went surgery at Kanazawa University Hospital. The
patients comprised 26 males and 22 females and ranged
in age from 37–91 years (mean 68.8 years). In addition
to the primary CRC tissue, FFPE specimens of matched
adjacent normal colon tissue, lymph node metastases
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7 of these patients, respectively. Tumor stage was
defined according to the International Union Against
Cancer (UICC) TNM system. Approval for this project
was obtained from the Kanazawa University Medical
Ethics Committee.
Tissue collection by LCM and macrodissection
All tissue samples were reviewed for quality and tu-
mor content, followed by histological diagnosis with
hematoxylin-eosin staining. Ten μm thickness sections
were placed on a special foil on a glass slide, deparaf-
finized with xylene and then hydrated and stained
with hematoxylin. Cells were collected using the Leica
AS LMD system (Leica mycrosystems, Wetzlar, Germany)
and captured into a microcentrifuge tube. To verify the
accuracy of capture, images of tissue sections taken before
and after microdissection were recorded. Representative
images were presented in Additional file 1: Figure S1. Cell
populations from three different areas were collected and
included the tumor center and invasive front for all 48 pri-
mary tumors. For 12 patients, matched epithelial cells
from normal mucosa and stromal cells surrounding the
tumor cells were also isolated. In 21 cases, metastatic
tumor cells from lymph nodes and/or distant metastases
were collected. In addition to the microdissected tissue
samples, a scalpel was used to collect macrodissected
tumor tissue for assessment of the influence of stromal
cell contamination and for analysis of microsatellite in-
stability (MSI) and CpG island methylator phenotype
(CIMP) status.
DNA isolation and bisulfite treatment
DNA was extracted from tissue samples using the
QIAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany)
and treated with bisulfite using the EpiTect bisulfite Kit
(Qiagen) according to the manufacturer’s protocols.
Multicolor MethyLight assay
LINE-1 methylation was measured using the MethyLight
assay [16] and the use of two different probes for
unmethylated- and methylated-LINE-1 sequences. These
were labelled with FAM and Yakima yellow, respectively.
Primers used for PCR (forward, GGGAGTGTTAGA
TAGTGGG; reverse, AAACTCCCTAACCCCTTA) con-
tained no CpG sites and amplifed the bisulfite-converted
LINE-1 sequence independently of its methylation sta-
tus. The two probes were synthesized by Nippon EGT
(Toyama, Japan) and consisted of FAM-CCTACTT
CAACTCACACACAATAC-Eclipse Dark Quencher and
Yakima yellow-CCTACTTCGACTCGCGCACGATAC-
Eclipse Dark Quencher. Locked nucleic acid was used
for the underlined nucleotides in order to match the
melting temperature between the probes. A standardsample was created by ligating unmethylated- and
methylated-LINE-1 sequences, and cloning into a plas-
mid (Additional file 2: Figure S2). Real-time detection
was performed simultaneously with the standard sam-
ple that was equivalent to 50% methylated LINE-1
sequence. The percentage of methylated LINE-1 was
calculated using the formula: 100 × methylated reaction /
(unmethylated reaction + methylated reaction).Analysis of MSI and CIMP
DNA isolated from macrodissected tissue was used for
the analysis of MSI and CIMP as described previously
[15]. MSI status was determined using 3 mononucleo-
tide repeat markers (BAT26, NR21 and NR27) and
CIMP by the methylation status of 5 genes (CACNA1G,
IGF2, NEUROG1, RUNX3 and SOCS1).Statistical analysis
Paired t-test was used for the comparison between the
LINE-1 methylation levels in different samples. The
Mann–Whitney U test or the Kruskal-Wallis test was
used to compare LINE-1 methylation levels between two
or three clinicopathological variables, respectively. All
statistical analyses were carried out using the R software
package version 2.7.2 [17].Results
Development and validation of a multicolor
MethyLight assay
In a previous study we developed a quantitative
methylation-specific PCR (qMSP) assay to measure
LINE-1 methylation [18]. This assay used methylation-
specific primers and SYBR green and was initially
employed here to analyze the microdissected samples.
However, the results obtained with this method were
not reproducible due to the low threshold cycle (data
not shown). We therefore developed a new multicolor
MethyLight assay to measure LINE-1 methylation with
high sensitivity and reproducibility. To validate this
method, samples with 10% increments in LINE-1 methy-
lation level were prepared by mixing varying ratios of
plasmids cloned with unmethylated- or methylated-
LINE-1 sequence. Using the multicolor MethyLight
assay, a linear increase in LINE-1 methylation was
observed in the prepared samples (Additional file 3:
Figure S3). To evaluate inter-assay variation, DNA from
four CRC cell lines with different LINE-1 methylation
levels was analyzed in four independent assays. The
inter-assay variation was within an acceptable range
(Additional file 4: Table S1). These results demonstrate
that the newly established assay was accurate and repro-
ducible across a range of LINE-1 methylation levels.
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Tumor samples microdissected from three different
areas of each primary tumor including the center and in-
vasive front were evaluated in duplicate by the multi-
color MethyLight assay. Samples with a low threshold
cycle value (<32) showed inconsistent results for dupli-
cate assays and were thus deemed as “not available”
(NA). All the results of the assay are shown in
Additional file 5: Table S2. The measurement of LINE-1
methylation was successful in 133/144 (92.4%) of the
microdissected samples from the primary tumors, des-
pite the small amounts of DNA collected by LCM. The
LINE-1 methylation level showed little intra-tumor het-
erogeneity, with all values from the same tumor being
within 10% difference. This level of difference is not
strong considering the distribution of the LINE-1 methy-
lation (range of 27.2 to 88.3%, Additional file 5: Table S2)
and up to 4.9% of the inter-assay variation (Additional file
4: Table S1). No significant difference was observed in
LINE-1 methylation between the central area and invasive
front from the same tumor (Figure 1A).
To investigate for possible differences in LINE-1
methylation between matched primary and metastatic
tumor tissues, tumor cells collected by LCM from lymph
node (18 cases) and distant metastases (7 cases) were
also evaluated. Distant metastases from liver (5 samples),
peritoneum (4 samples) and ovarium (1 sample) were
available for the analysis. The mean LINE-1 methylation


































































































Figure 1 LINE-1 methylation at multiple tumor sites. LINE-1
methylation level was compared between cancer cells from the
center and invasive front of the tumor (A), and between the primary
tumor and lymph node metastasis (B).was identical to that found in metastatic lymph nodes
(Figure 1B). No significant difference in the methylation
between primary tumor and distant metastases was
observed (Table 1). These results demonstrate there is lit-
tle intra-patient heterogeneity for LINE-1 methylation and
that it remains relatively stable during CRC progression.
Contamination of tumor sample with stromal
cells significantly influences the measurement of
LINE-1 methylation
Cancer cells and surrounding stromal cells and normal
mucosal cells were obtained from 12 primary tumors
and matched adjacent colonic mucosa using LCM. Con-
sistent with a previous report [13], LINE-1 methylation
level was significantly lower in tumor cells compared to
stromal and adjacent normal cells (Figure 2A). This find-
ing suggests that a high content of stromal cells could
influence the accuracy of LINE-1 methylation measure-
ment in tumor samples. To investigate this, we com-
pared microdissected and macrodissected tumor samples,
with the latter having moderate-heavy contamination of
stromal cells. LINE-1 methylation was significantly lo-
wer in the microdissected samples compared to the
macrodissected samples (P<0.0001, Figure 2B), with
the former also showing more cases with low levels
of methylation (Figure 2C).
Associations between LINE-1 methylation and
clinicopathological characteristics
Amongst the 48 primary CRC, 3 were CIMP-positive/
microsatellite stable, 1 was CIMP-positive/MSI and 1 was
CIMP-negative/MSI. These phenotypes show high LINE-1
methylation [19,20] and distinct clinicopathological fea-
tures [21,22] and were therefore excluded from the ana-
lysis. Table 2 summarizes the associations between LINE-
1 methylation in primary tumors and the clinicopathologi-
cal characteristics of CIMP-negative/microsatellite stableTable 1 LINE-1 methylation level in the primary tumor
and in synchronous metastases of CRC
LINE-1 methylation level (%)
Patient ID Primary Metastatic sites
Lymph node Liver Peritoneum Ovarium
12 73.4 NA 78.0 NA NA
18 43.5 39.6 38.7 NA NA
27 48.2 NA NA 40.6 NA
29 59.5 64.7 66.9 65.2 NA
30 70.0 72.1 77.7 70.8 67.5
36 77.5 73.4 NA 74.6 NA
40 70.0 NA 66.6 NA NA
The LINE-1 methylation level at the primary tumor site is the mean value of assay
results from multiple areas including the tumor center and invasion front.
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Figure 2 Influence of stromal cell contamination of the tumor sample on results from the LINE-1 methylation assay. (A) LINE-1
methylation levels in tumor, stromal and normal cells. (B) LINE-1 methylation levels in microdissected tumor cells and in macrodissected tumor
tissues. (C) Distribution of LINE-1 methylation levels in microdissected tumor cells (upper panel) and in macrodissected tumor tissues (lower panel).
Table 2 Associations between LINE-1 methylation in
primary CRC and clinicopathological features
n LINE-1 methylation p-value
Age >70 22 69.5 (62.1 – 70.7) 0.17
≤70 21 59.5 (48.4 – 73.4)
Gender male 25 64.4 (48.9 – 70.4) 0.49
female 18 68.3 (52.3 – 74.3)
Site proximal 19 65.3 (53.2 – 69.8) 0.77
distal 24 69.3 (49.0 – 73.8)
Histology well 16 68.6 (49.0 – 72.1) 0.98
moderately 27 65.7 (54.8 – 71.9)
T factor 1 1 76.3 0.55
2 7 67.3 (49.3 – 70.7)
3 26 67.3 (49.3 – 70.7)
4 9 58.2 (48.2 – 69.3)
N factor 0 20 69.5 (49.7 – 75.0) 0.67
1 16 59.4 (48.9 – 74.1)
2 7 65.7 (62.9 – 68.0)
M factor 0 34 67.3 (50.3 – 73.8) 0.49
1 9 60.7 (48.2 – 70.0)
Stage I 4 72.3 (69.5 – 75.0) 0.47
II 15 69.3 (49.4 – 73.8)
III 15 64.4 (50.5 – 68.1)
IV 9 60.7 (48.2 – 70.0)
n, number of patients.
LINE-1 methylation levels are shown as the median (25th percentile –
75th percentile).
Histology of adenocarcinoma was sub-classified into well- and moderately-
differentiated adenocarcinoma according to their grading.
TNM factors and stage were defined according to the International Union
Against Cancer (UICC) TNM system.
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could be due to the small sample size. Consistent with a
previous report [13], LINE-1 methylation level was lower
in the CRC with advanced stage.
Discussion
LINE-1 hypomethylation has been observed in various
malignancies and suggested to play a role in carcino-
genesis. Although an association between LINE-1 me-
thylation level and disease stage has been reported in
leukemia [23], colorectal [13] and lung cancers [24], the
underlying mechanism for this association is unknown.
Sunami et al. proposed the concept of a progressive loss
of genomic methylation during CRC development [13],
as illustrated in Figure 3A. This concept involves that ac-
quisition of metastatic potential in CRC is accompanied
by decrease of LINE-1 methylation. From this, it could
be expected that LINE-1 methylation level would be
lower in metastatic CRC tissue compared to the primary
tumor of the same patient if metastasis occurs by a clone
of cancer cell with lower LINE-1 methylation. However,
our results showed almost identical LINE-1 methylation
levels between primary and metastatic sites (both lymph
node and distant). Our observation may represent that
LINE-1 methylation level is identical between primary
tumor cells and metastatic clone, and cannot exclude
the concept illustrated in Figure 3A. Nevertheless, it
might be unlikely that the LINE-1 methylation is pro-
gressively decreased with same grade even in these dif-
ferent cells that reside in different environment including
primary, lymph node and distant metastatic sites.
We propose another explanation for the association of
LINE-1 methylation with disease stage in Figure 3B. This































Figure 3 Possible models to explain the association between
LINE-1 hypomethylation and CRC progression. (A) In the
prevailing model, LINE-1 methylation decreases progressively during
CRC progression. (B) In an alternate model, LINE-1 methylation is
stable during CRC progression and the time of diagnosis may be the
critical factor that determines the observed association between
methylation level and disease stage. In both models, the solid line
shows a change of LINE-1 methylation during CRC progression
and the arrowhead indicates the time of diagnosis, surgery and
sample collection.
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sion and takes into account the time of diagnosis. Can-
cers with low LINE-1 methylation levels can progress
rapidly because they have unstable genomes, more fre-
quent transposition and may be difficult to diagnose
early. Such a case is represented by the long arrow in
Figure 3B. If the CRC arises within a polyp that has high
LINE-1 methylation, such as a serrated adenoma/polyp
[25,26], this type of cancer is more likely to be detected
early by colonoscopy. In contrast, if the CRC arises
within a flat or depressed type of tumor with low LINE-
1 methylation, it will be much harder to detect by colon-
oscopy. Further investigations into LINE-1 methylation
and cancer progression are required to test this concept.
Possible associations between LINE-1 methylation andthe morphology of early stage CRC should also be the
subjects of further studies.
LINE-1 methylation is an ideal molecular marker be-
cause it exhibits little intra-tumoral heterogeneity. Mo-
lecular analysis is usually performed on a small portion
of the surgical specimen of primary tumor. In the neoad-
juvant setting, tumor tissue obtained by preoperative
endoscopic biopsy is used instead of the surgical sample.
Intra-tumoral genetic heterogeneity for K-ras and p53
gene mutations has been demonstrated in CRC tissue
[27,28]. DNA methylation may show greater heterogen-
eity than gene mutations because it is a reversible modi-
fication. Tumor heterogeneity in samples used for
molecular analysis can give rise to false positives and
negatives that lead to diagnostic and therapeutic failure.
Only one study has so far addressed the issue of intra-
tumoral heterogeneity for LINE-1 methylation [13]. This
work reported no significant difference in methylation
between samples from the luminal surface and those
from the most invasive primary tumor site, which is con-
sistent with our data showing no significant difference in
methylation between the central area and invasive front
from the same tumor. However, there was a weak differ-
ence of less than 10% in the LINE-1 methylation level
between three analyzed areas, suggesting that some
CRCs might have weak heterogeneity in the LINE-1
methylation level. Although further study is required
to demonstrate how stable the LINE-1 methylation is
in a primary tumor, sampling errors due to strong
intra-tumoral heterogeneity are not the case for this
molecular marker.
Because the present work found that LINE-1 methyla-
tion level was identical between matching primary and
metastatic tumor tissues, the molecular analysis of this
marker can be performed using tissue samples from ei-
ther of these sites. Secondary tumor tissues are not rea-
dily accessible and hence the molecular features of a
metastatic tumor must sometimes be evaluated using
the primary tumor, although the reverse is sometimes
also the case. The LINE-1 methylation level of an indi-
vidual CRC patient can therefore be represented by a
single sample from any site. One limitation of our work
is that cases of metachronous metastases were not
included in the CRC study cohort. Considering the long
natural history of CRC development, the primary tumor
and synchronous metastases evaluated here were from
the same time period and hence this could account for
the identical levels of LINE-1 methylation. Lower LINE-
1 methylation due to clonal evolution might be observed
in metachronous metastases. Furthermore, discordance
in the LINE-1 methylation level between primary tumor
and metachronous metastases might arise in recurrent
CRC following chemotherapy. Molecular analysis of
relapsed cancer is generally performed on the primary
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current cancer sites. Future studies should compare
primary tumors and metachronous metastases from in-
dividual patients.
In order to use LINE-1 methylation for routine clinical
application, LCM is necessary to avoid erroneous results
caused by stromal cell contamination. The present study
is the first to compare the results for LINE-1 methyla-
tion between samples prepared with and without micro-
dissection. LINE-1 methylation level was significantly
lower in microdissected compared to macrodissected
samples (Figure 2B), demonstrating that measurement of
this marker may be inaccurate in tumor samples that
have not undergone LCM enrichment. Continuous vari-
ables are often stratified into a small number of groups.
Absolute assay values are therefore not critical provided
their distribution shows a similar pattern between micro-
and macro-dissected samples and patients are stratified
according to this pattern. However, we observed a con-
siderable alteration in the distribution of LINE-1 methy-
lation values due to contamination with stromal cells
(Figure 2C), making it more difficult to achieve accurate
stratification of patients. We therefore recommend LCM
of tumor samples in order to achieve accurate quantifica-
tion of LINE-1 methylation.
The multicolor MethyLight assay developed in this
study allows the analysis of LINE-1 methylation even in
the small amounts of DNA obtained from microdis-
sected samples. Although LINE-1 consists of many num-
bers of variants [9,29], our MethyLight assay only
measures the one of variants, L1.2 (M80343). This major
variant of LINE-1 sequence presents in human genome
with about 16000 copies compared to single copy gene
of ACTB, which is estimated by qPCR and ddCt method
(data not shown). The high copy number suggests that
the L1.2 sequence can be used to estimate global methy-
lation status. In addition, there was significant relation-
ship between the LINE-1 methylation level measured by
this MethyLight assay and those measured by previously
developed qMSP assay [18] (Additional file 6: Figure S4).
The latter assay was not compatible to microdissected
samples but used in our previous studies to demonstrate
clinical significance of LINE-1 methylation [15,24]. To-
gether, the new MethyLight assay could be used in
broader clinical appreciation than the qMSP assay and
in further validation studies of clinical significance of the
LINE-1 methylation.
Conclusions
We have demonstrated that LINE-1 methylation level
shows little intra-patient heterogeneity, thus making it
suitable for possible clinical applications in CRC. LINE-1
methylation appears to be relatively stable during CRC
progression. We propose a new concept to explain therelation between LINE-1 methylation and disease stage.
Further studies are required to establish whether LINE-1
methylation could be used in personalized medicine for
CRC and to better understand its role in cancer progres-
sion and metastasis.
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